Skip to main content
. 2019 Sep 2;10:3941. doi: 10.1038/s41467-019-11853-y

Fig. 4.

Fig. 4

Survival outcomes with varying chemotherapy intensities for the respective response phenotypes. Disease-free (DFS), overall (OS), distant metastasis-free (DMFS), and locoregional relapse-free survival (LRFS) for a intermediate and late responders with complete biological response (cBR) post-IC2, b intermediate and late responders without cBR post-IC2 and c treatment-resistant subgroup